A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, open label trial for patients with multiple myeloma in first relapse.
Trial will compare tanespimycin (KOS-953), in combination with a fixed dose of bortezomib
versus bortezomib alone.